Use-centered design

I'm a microbiologist and here's what (and where) I never eat

Retrieved on: 
Thursday, September 28, 2023

Every year, around 2.4 million people in the UK get food poisoning – mostly from viral or bacterial contamination. Most people recover within a few days without treatment, but not all are that lucky. As a microbiologist, I’m probably more acutely aware of the risk of food-borne infections than most. Here are some of the things I look out for.Eating outdoors I rarely eat alfresco – whether picnics or barbecues – as the risk of food poisoning goes up when food is taken outdoors.

Key Points: 


Every year, around 2.4 million people in the UK get food poisoning – mostly from viral or bacterial contamination. Most people recover within a few days without treatment, but not all are that lucky. As a microbiologist, I’m probably more acutely aware of the risk of food-borne infections than most. Here are some of the things I look out for.

Eating outdoors

    • I rarely eat alfresco – whether picnics or barbecues – as the risk of food poisoning goes up when food is taken outdoors.
    • You can use alcohol hand gels (they’re better than nothing), but they don’t kill all germs.
    • For barbecues, meat needs to be thoroughly cooked, and a meat thermometer is a good investment to avoid food poisoning.

Buffets

    • Contamination comes from buffet visitors touching food, and germs can be sprayed on to buffets from people sneezing or coughing close to the food.
    • The problem is buffets tend to be laid out before you arrive, so it is difficult to tell if the platters of cooked meat, seafood, salads, desserts and appetisingly arranged fruit and vegetables will have been sitting for more than two hours when you come to eat them.
    • For hot buffets, such as those served at breakfast in hotels, I always avoid lukewarm food, as bacteria that cause food poisoning can grow quickly when food is kept at less than 60℃.

Oysters

    • There are some foods I never eat, and raw shellfish, such as oysters, is one of them.
    • This is because oysters are filter feeders and can concentrate germs, such as Vibrio and norovirus, in their tissue.

Bagged salads

    • I never eat bagged salads, largely because one of my research areas is fresh salad safety.
    • It has been found that bagged lettuce can contain food poisoning germs such as E coli, Salmonella and Listeria.

Cooking practices

    • In terms of cooking practices, I have a list of dos and don’ts.
    • One of my “never do” practices is reheating cooked rice.
    • Although the Bacillus cells are killed by cooking, the spores survive.

Dining out

    • I never collect “doggy bags” of food leftovers (they have usually exceeded the two-hour time limit), even if they really are intended for a pet.
    • The benefits of being a microbiologist are that we know how to avoid food poisoning and, in return, people have confidence our cooking is very safe to eat.

Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic

Retrieved on: 
Tuesday, September 26, 2023

Todos intends to deploy medical foods to aid physicians in the dietary management of Long COVID, optimize immune support with nutritional supplements targeting the 3CL protease, and precision diagnostic panels to assist in the diagnosis and monitoring of Long COVID patients.

Key Points: 
  • Todos intends to deploy medical foods to aid physicians in the dietary management of Long COVID, optimize immune support with nutritional supplements targeting the 3CL protease, and precision diagnostic panels to assist in the diagnosis and monitoring of Long COVID patients.
  • A recent report by David Cutler of Harvard University estimates the annual Long COVID cost to the US economy is $3.7 trillion.
  • With this signed agreement now in place, the Company is now able to swiftly implement our strategy of crowdfunding within the 3CL Pharma entity to fund a Long COVID clinical trial.
  • Our objective is to become the go to lab for Long COVID diagnosis and monitoring, including for clinical trials and investigational biomarkers, to support the Long COVID community health journey.

FDA Clears Numares Health Cardiovascular Diagnostic Test and Core Technology Platform

Retrieved on: 
Monday, July 31, 2023

The FDA clearance also includes the company's core technology platform, the proprietary AXINON® System, that incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.

Key Points: 
  • The FDA clearance also includes the company's core technology platform, the proprietary AXINON® System, that incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.
  • Numares uses this technology to develop diagnostic tests for chronic heart, kidney and liver diseases.
  • This FDA clearance of the AXINON® technology provides a pathway for more rapid FDA clearance of other tests currently in development.
  • A second Numares assay is expected to gain FDA 510(k) clearance later this year, the AXINON® GFR(NMR) kidney function assay.

STIs are on the rise – here's how to navigate telling a partner if you've got one

Retrieved on: 
Tuesday, July 25, 2023

The number of gonorrhoea diagnoses recorded in England was in fact the highest since annual records began.

Key Points: 
  • The number of gonorrhoea diagnoses recorded in England was in fact the highest since annual records began.
  • On one hand you are being honest, responsible and respectful to your partner (or partners), and protecting their health.
  • The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.
  • Letting sexual partners know if you have an STI is essential to the prevention, treatment and control of these infections.

Honesty is the best policy

    • For example, a single course of antibiotics will often clear chlamydia, gonorrhoea, syphilis and “trich” (trichomoniasis).
    • It’s totally normal to be anxious about your partner’s response and the potential effect on your relationship, whether casual or long term.
    • It’s also important to disclose if you have an STI before starting a sexual relationship with someone new.

What if a partner discloses that they have an STI?

    • When asking these questions, try to be mindful of the language you use, and avoid placing blame.
    • An early STI diagnosis is the best opportunity for effective treatment, and prevention of health complications and further transmission.
    • If you do decide to have sex, it’s advisable to use a physical barrier such as a condom or dental dam to protect your partner.

Make this an opportunity

    • Whether it’s you or your partner who have an STI – or both – use this opportunity to do some research on sexual health.
    • The COVID pandemic has also shown us the crucial role of early detection, rapid testing, and importantly, public health communication and education.
    • Overcoming STI stigma, much like COVID stigma, requires education, improving access to STI testing and treatment, and the promotion of inclusive conversations about sexual health.

FDA Clears Numares Health Cardiovascular Diagnostic Test and Core Technology Platform

Retrieved on: 
Tuesday, July 25, 2023

The US Food and Drug Administration has cleared a Numares Health test, the AXINON® LDL-p Test System

Key Points: 
  • The US Food and Drug Administration has cleared a Numares Health test, the AXINON® LDL-p Test System
    The FDA clearance also includes the company's core technology platform, the proprietary AXINON® System, that incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.
  • Numares uses this technology to develop diagnostic tests for chronic heart, kidney and liver diseases.
  • This FDA clearance of the AXINON® technology provides a pathway for more rapid FDA clearance of other tests currently in development.
  • A second Numares assay is expected to gain FDA 510(k) clearance later this year, the AXINON® GFR(NMR) kidney function assay.

FDA Clears Numares Health Cardiovascular Diagnostic Test and Core Technology Platform

Retrieved on: 
Tuesday, July 25, 2023

The FDA clearance also includes the company's core technology platform, the proprietary AXINON® System, that incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.

Key Points: 
  • The FDA clearance also includes the company's core technology platform, the proprietary AXINON® System, that incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.
  • Numares uses this technology to develop diagnostic tests for chronic heart, kidney and liver diseases.
  • This FDA clearance of the AXINON® technology provides a pathway for more rapid FDA clearance of other tests currently in development.
  • A second Numares assay is expected to gain FDA 510(k) clearance later this year, the AXINON® GFR(NMR) kidney function assay.

First Long COVID Diagnostic Test Launches Across Australia

Retrieved on: 
Tuesday, May 16, 2023

The first diagnostic test for long COVID is now available to patients across Australia.

Key Points: 
  • The first diagnostic test for long COVID is now available to patients across Australia.
  • The test can help physicians diagnose long COVID by differentiating it from other diseases with similar symptoms, and to design personalized treatment approaches.
  • Persistent COVID, or long COVID, is a multiorgan symptomatic complex with symptoms persisting over time.
  • A diagnostic test to identify patients with long COVID, using objective measures of immune biomarkers, is an essential first step for treatment.

Five-Year Results of the LEOPARD Trial published in the Journal of Vascular Surgery (JVS)

Retrieved on: 
Thursday, April 27, 2023

Endologix LLC , a privately held global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the final five-year results of the LEOPARD Trial in the Journal of Vascular Surgery ( JVS1 ).

Key Points: 
  • Endologix LLC , a privately held global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the final five-year results of the LEOPARD Trial in the Journal of Vascular Surgery ( JVS1 ).
  • "We are proud to have conducted the first randomized controlled trial comparing commercially available endografts, and we remain committed to providing the highest quality clinical evidence that underpins our life-changing vascular therapies.
  • LEOPARD was a prospective, randomized, multi-center trial that enrolled 455 patients across 56 US Centers.
  • Five-Year Results of the LEOPARD Trial of Commercially Available Endografts.

Destiny Management's 'Conquer Diabetes' Course is Accredited by the American Diabetes Association

Retrieved on: 
Sunday, March 26, 2023

Wellton, Arizona--(Newsfile Corp. - March 26, 2023) - Destiny Management is excited to announce that its flagship course 'Conquer Diabetes' has been approved by the American Diabetes Association as an accredited Diabetes Self-Management Education and Support (DSMES) course.

Key Points: 
  • Wellton, Arizona--(Newsfile Corp. - March 26, 2023) - Destiny Management is excited to announce that its flagship course 'Conquer Diabetes' has been approved by the American Diabetes Association as an accredited Diabetes Self-Management Education and Support (DSMES) course.
  • 'Conquer Diabetes' is designed to bridge the gap between medical interventions and fitness, helping patients with diabetes learn about their unique situation and how to manage their blood sugar accordingly.
  • Co-Founder Terry Linde developed the 'Conquer Diabetes' program after working with a Type 1 diabetic patient and her family for over 25 years.
  • To explore a condensed version of the course, visit https://bit.ly/3f97j5v ,
    or to sign up for the full course, you can visit https://destinymanagementllc.vipmembervault.com/ .

Therapeutic Solutions International Spin Off Campbell Neurosciences Creates Saliva Based Test for Suicidal Ideations

Retrieved on: 
Monday, March 20, 2023

Therapeutic Solutions International (TSOI) announced today its Spin Off Company, Campbell Neurosciences, Inc., obtained successful validation of its suicidal ideation predictive test using a saliva based system.

Key Points: 
  • Therapeutic Solutions International (TSOI) announced today its Spin Off Company, Campbell Neurosciences, Inc., obtained successful validation of its suicidal ideation predictive test using a saliva based system.
  • Previously the Company reported successful stratification of suicidal tendencies using a proprietary blood-based biomarker.
  • Additionally, suicide is the second leading cause of death among individuals between the ages of 10-34.
  • “The prospects of a simple saliva-based test will allow for a more personalized approach to regenerative psychiatry, which in the end will result in more lives saved,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International.